CN102512663B - Application of nerve growth factor in preparing medicines for treating pruritus - Google Patents
Application of nerve growth factor in preparing medicines for treating pruritus Download PDFInfo
- Publication number
- CN102512663B CN102512663B CN 201110415928 CN201110415928A CN102512663B CN 102512663 B CN102512663 B CN 102512663B CN 201110415928 CN201110415928 CN 201110415928 CN 201110415928 A CN201110415928 A CN 201110415928A CN 102512663 B CN102512663 B CN 102512663B
- Authority
- CN
- China
- Prior art keywords
- growth factor
- nerve growth
- injection
- application
- described application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an application of a nerve growth factor (NGF) in preparing medicines and daily chemical products for treating pruritus. According to the invention, an effective therapeutic method for pruritus can be provided, and a novel approach for improving the life quality of pruritus patients is provided.
Description
Technical field
The invention belongs to medical technical field, be specifically related to the application of nerve growth factor in preparation treatment skin pruritus disease medicament.
Background technology
Nerve growth factor (Nerve Growth Factor, NGF) is a kind of micromolecule polypeptide class neurotrophic factor, has stronger short cell division function, plays an important role in all many-sides such as neurodevelopment, neuranagenesis.
In recent years, NGF is with its unique mechanism of action and advantage, be widely used clinically, mainly concentrate on the following aspects: (1) nervus centralis disease (Central Nerve System, CNS): cerebral apoplexy, spinal cord injury, craniocerebral trauma, neonatal hypoxic ischemic encephalopathy and Alzheimer (Alzheimer ' s Disease, AD) etc.; (2) peripheral nerve injury and peripheral nerve disease (Peripheral Nerve System, PNS): diabetic peripheral neuropathy, the injury repairing of nervus facialis, organophosphate poisoning Delayed onset peripheral neuritis and injury of sciatic nerve etc.; (3) ocular disease: treatment neurotrophic corneal ulcer, optic neuritis, promotion cornea wound healing etc.
Skin pruritus is one of common dermatosis of clinical patient, especially is more common in the old people.It is characterized by take pruritus as main, and without primary lesion.According to the difference of pruritus scope, clinically it is divided into two kinds of limitation and generals.
Skin pruritus is without former breakout, will only have skin pruritus clinically and is referred to as pruritus without the primary cutaneous impairer.The category that belongs to the traditional Chinese medical science " pruritus ".Skin pruritus is divided plain edition and anaphylactic type.But whole body occurs, especially take face, the back of the body and extremity as many.The plain edition skin pruritus generally is that the skin too dry causes, and the cause of disease of skin pruritus does not still understand, thinks relevant with some disease, such as diabetes, hepatopathy, nephropathy etc. more; Simultaneously also with some extraneous factors stimulate relevant, such as cold, warm, chemical ﹠ blended fabric etc.
In above-mentioned disease, the patient tends to cause secondary affection owing to the endurable pruritus is scratched, and causes the infringements such as the hyperemia of pruritus position, ulceration, lichen sample words, pigmentation, also can have a sleepless night because itching and maybe can not sleep peacefully.This not only perplexs extensive patients, also is the thorny difficult problem that the dermatologist feels.At present, the Western medicine for the treatment of skin pruritus commonly used has antihistaminic (terfenadine, clarityne) calcium preparation (common calcium tablet, necessity gives injection) and hormone (containing the dexamethasone class) etc.Because these medicine contraindications are many, often cause drowsiness, weak and other side effect, affect patient's orthobiosis and work.
Skin pruritus belongs to the neuropsychiatric dermatosis, is a kind of skin neurosis illness, perhaps can solve the problem of skin pruritus so infer micromolecule polypeptide class neurotrophic factor NGF, now not yet has to studies show that NGF has the function for the treatment of skin pruritus.
Summary of the invention
The object of the present invention is to provide the application of nerve growth factor in preparation treatment skin pruritus disease medicament.
Preferably, nerve growth factor described in the above-mentioned application adopts topical administration.
Preferably, nerve growth factor described in the above-mentioned application adopts drug administration by injection.
Preferably, nerve growth factor described in the above-mentioned application adopts the subcutaneous injection administration.
Preferably, nerve growth factor described in the above-mentioned application adopts administered intramuscular.Preferably, nerve growth factor described in the above-mentioned application adopts percutaneous or mucosal route administration.
Preferably, nerve growth factor described in the above-mentioned application adopts nasal mucosa medicine administration.
Preferably, the dosage form of described nasal mucosa medicine administration is nasal spray, nasal drop, nose solution, nasal obstruction agent and nose aerosol.
Preferably, described skin pruritus disease is the skin pruritus that mosquito bite causes.
Preferably, described skin pruritus disease is old people's skin pruritus.Preferably, the patient of skin pruritus disease described in the above-mentioned application is the old people.
Preferably, described skin pruritus is the geroderma pruritus that unknown cause causes.Preferably, described skin pruritus is the geroderma pruritus that is caused by basic disease.Preferably, described basic disease is hypertension, hepatic disease, kidney disease, cancer, diabetes.
Preferably, the dosage of described nerve growth factor was 5～400 microgram/days, preferably 10～100 microgram/days.Preferably the dosage of described nerve growth factor was 30～50 microgram/days, was preferably for 30 microgram/days.
Nerve growth factor (Nerve Growth Factor, NGF) is a kind of micromolecule polypeptide class neurotrophic factor, has stronger short cell division function, plays an important role in all many-sides such as neurodevelopment, neuranagenesis.But in clinical practice, the inventor is surprised to find that nerve growth factor has the significant effect of improving for skin pruritus.
Pruritus is a kind of subjective symptoms, pathogeny is still imprecise, it is generally acknowledged that the free nerve endings that reaches high dermis in the epidermis is the sensor that pruritus is felt, sensor is subjected to cause the chemical mediators such as local histamine, kassinin kinin and protease to discharge after physics, the chemical stimulation, these chemical mediators act on teleneuron and cause impulsion, in the pain nerve fiber without sheath cell tissue fibers conduction, via spinothalamic tract to thalamus, arrive at last the cerebral cortex sensory region, produce tickle and itch.
By enforcement of the present invention, can provide a kind of effective Therapeutic Method to skin pruritus, for the quality of life of improving the pruritus crowd provides a kind of new approach.
The specific embodiment
The present invention is described further below in conjunction with test example, and following embodiment only limits to illustrate the present invention, and should not be considered as limiting protection scope of the present invention.
The skin pruritus that clinical trial example 1 treatment mosquito bite causes
1.1 physical data: this group patient 125 examples, male 60 examples wherein, women 65 examples, 18～51 years old age.
1.2 using method:
1.2.1 medicine: injection mouse nerve growth factor (Soviet Union's peptide is given birth to Shutaishen (Beijing) Pharmaceutical Co., Ltd.), essential balm is organized in contrast
1.2.2 concrete using method: directly medicine is smeared every day 2～3 times, SM 1～5 day during mosquito bite aftersensation pruritus
Method for preparation of drug: get one bottle of injection mouse nerve growth factor (30 μ g/ bottle), inject 2mL physiological saline solution mix homogeneously, get the NGF solution of 15 μ g/mL, save backup in 2～8 ℃ of refrigerators.
1.2.3 criterion of therapeutical effect: see Table 1
Table 1 criterion of therapeutical effect
| Classification | Standard |
| Cure | Erythra and scratchiness disappear fully |
| Produce effects | Erythra disappears substantially, and scratchiness is conscious to be alleviated |
| Effectively | Deflorescence is more than 50% |
| Invalid | Treat that erythra and scratchiness have no improvement after 5 days |
1.3 therapeutic outcome
Table 2 therapeutic outcome
| Medicine | Number of users | Cure | Produce effects | Effectively | Invalid | Total effective rate |
| Essential balm | 62 | 11(18％) | 26(42％) | 25(40％) | 60％ | |
| NGF | 63 | 51(81％) | 9(14％) | 2(3％) | 1(2％) | 98％ |
By upper table 2 as can be known, essential balm can not be cured the pruritus that mosquito bite causes substantially, and total effective rate can reach 60%; And injection mouse nerve growth factor of the present invention is when being used for pruritus that mosquito bite causes, and cure rate can reach 81%, and total effective rate has reached 98%.
Clinical trial example 2 treatment old people skin pruritus
1.1 physical data: this organizes 280 routine patients, male 160 examples, women 120 examples, age 55-86 year, average 72.5 years old.The course of disease is the shortest 1 year, and is the longest 5 years, average 2.6 years.Wherein, among the described patient 280 routine patients, with basic disease such as the patient of hypertension, liver, kidney, cancer, diabetes totally 165 examples, be divided at random three groups (essential balm group, NGF percutaneous dosing group, NGF nasal-cavity administration group, NGF injection groups).
Except patient main suit's pruritus misery, extremity and trunk visible obviously scratch, blood crusts are simultaneously with vexed, insomnia.
1.2 Therapeutic Method:
1.2.1 medicine: injection mouse nerve growth factor (Soviet Union's peptide is given birth to Shutaishen (Beijing) Pharmaceutical Co., Ltd.), mouse nerve growth factor nasal spray (the clear new drug development center of spreading out, Beijing provides) uses essential balm in contrast.
1.2.2 concrete using method
The intramuscular injection group: every bottle of injection mouse nerve growth factor (30 μ g/ bottle) dissolves with 0.5ml sodium chloride injection (or sterilized water for injection) before use, stores to get final product in 2～8 ℃ of refrigerators.μ g every days 30 (one bottle), 1 time on the one, 3～6 weeks were a course for the treatment of;
The percutaneous dosing group: every bottle of injection mouse nerve growth factor (30 μ g/ bottle) dissolves with 0.5ml sodium chloride injection (or sterilized water for injection) before use, stores to get final product in 2～8 ℃ of refrigerators.Medicine directly is applied on the skin every day 2～3 times, 3～6 weeks of SM;
The nasal-cavity administration group: every bottle of injection mouse nerve growth factor (30 μ g/ bottle) dissolves with 0.5ml sodium chloride injection (or sterilized water for injection) before use, then with gained NGF filled with solution (1mL/ bottle) in jetmizer, place to store in 2～8 ℃ of refrigerators to get final product.One bottle of every day, 2 times on the one every side 0.125ml of bilateral nostril administration, 3～6 weeks were a course for the treatment of.
1.3 criterion of therapeutical effect: see Table 3
Table 3 criterion of therapeutical effect
1.4 therapeutic effect: see Table 4
Table 4 therapeutic outcome
By upper table 4 as can be known, essential balm can not be cured old people's skin pruritus substantially, and total effective rate only has 42%; And injection mouse nerve growth factor of the present invention no matter administering mode be directly smear, nasal-cavity administration or injection, cure rate all can reach more than 70%, total effective rate has all reached 97%, wherein use the direct injection approach, cure rate and total effective rate are higher, can reach 84%, total effective rate has reached 100%.
Simultaneously, in drug use process of the present invention, do not find that the side effect such as drowsiness, Liver and kidney toxicity appear in any patient.
The above only is preferred embodiment of the present invention, and is in order to limit the present invention, within the spirit and principles in the present invention not all, any modification of doing, is equal to replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (10)
1. the application of injection mouse nerve growth factor in the medicine of skin pruritus disease that preparation treatment mosquito bite causes or old people's skin pruritus disease.
2. according to claim 1 described application is characterized in that described nerve growth factor adopts drug administration by injection.
3. according to claim 2 described application is characterized in that described nerve growth factor adopts the subcutaneous injection administration.
4. according to claim 2 described application is characterized in that described nerve growth factor adopts administered intramuscular.
5. according to claim 2 described application, the dosage form that it is characterized in that described drug administration by injection are solution type injection agent, floating type injection, emulsion-type injection, injection freeze-dried powder or injectable sterile powder.
6. according to claim 1 described application is characterized in that described nerve growth factor adopts percutaneous or mucosal route administration.
7. according to claim 6 described application is characterized in that described nerve growth factor adopts nasal mucosa medicine administration.
8. according to claim 7 described application, the dosage form that it is characterized in that described nasal mucosa medicine administration are nasal spray, nasal drop, nose solution, nasal obstruction agent and nose aerosol.
9. according to claim 1～8 arbitrary described application, the dosage that it is characterized in that described nerve growth factor were 5～400 microgram/days.
10. according to claim 9 described application, the dosage that it is characterized in that described nerve growth factor were 10～100 microgram/days.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110415928 CN102512663B (en) | 2010-12-31 | 2011-12-14 | Application of nerve growth factor in preparing medicines for treating pruritus |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010615769.6 | 2010-12-31 | ||
| CN201010615769 | 2010-12-31 | ||
| CN 201110415928 CN102512663B (en) | 2010-12-31 | 2011-12-14 | Application of nerve growth factor in preparing medicines for treating pruritus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102512663A CN102512663A (en) | 2012-06-27 |
| CN102512663B true CN102512663B (en) | 2013-10-23 |
Family
ID=46283914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110415928 Active CN102512663B (en) | 2010-12-31 | 2011-12-14 | Application of nerve growth factor in preparing medicines for treating pruritus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102512663B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101035551A (en) * | 2004-10-19 | 2007-09-12 | 碧雅诗株式会社 | Nerve growth factor production inhibitor and external preparation for skin, cosmetic, quasi medicine, itch prophylactic and therapeutic agent and atopic dermatitis therapeutic agent mixed with the ner |
-
2011
- 2011-12-14 CN CN 201110415928 patent/CN102512663B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101035551A (en) * | 2004-10-19 | 2007-09-12 | 碧雅诗株式会社 | Nerve growth factor production inhibitor and external preparation for skin, cosmetic, quasi medicine, itch prophylactic and therapeutic agent and atopic dermatitis therapeutic agent mixed with the ner |
Non-Patent Citations (2)
| Title |
|---|
| 李萍 等.神经生长因子在特应性皮炎患者血中的检测及意义.《十五次全国皮肤性病学术年会》.2009,93-94. |
| 神经生长因子在特应性皮炎患者血中的检测及意义;李萍 等;《十五次全国皮肤性病学术年会》;20090616;93-94 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102512663A (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101800851B1 (en) | Local anesthesia pain-relieving time-delay angent | |
| EP3369428B1 (en) | External traditional chinese medicine preparation for diminishing inflammation, relieving pain and promoting fast healing, and preparation method therefor | |
| JP3989188B2 (en) | Bee venom therapy without a bee needle | |
| CN102512663B (en) | Application of nerve growth factor in preparing medicines for treating pruritus | |
| RU2463045C1 (en) | Method of treating cerebrovascular diseases and asthenic syndrome | |
| CN107349310B (en) | Traditional Chinese medicine composition for treating cancer pain and application thereof | |
| CN103272195B (en) | Traditional Chinese medicine paste for treating pain | |
| US20190328814A1 (en) | Anti-inflammatory, Analgesic and Fast-healing External Traditional Chinese Medicine Preparation and Its Preparation Method | |
| CN102205023B (en) | Powder for diminishing inflammation and healing trauma | |
| CN101829328A (en) | Drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome | |
| CN105168503B (en) | It is a kind of to be used to prevent external medicine composition of radiodermatitis and preparation method thereof | |
| CN104800264B (en) | One kind carries medicine acupuncture needle and application thereof | |
| CN108635418A (en) | A kind of little Jin gel combinations and preparation method thereof and purposes | |
| CN117018158B (en) | Graphene acupoint plaster for warming uterus and relieving pain as well as preparation method and application thereof | |
| CN101411700B (en) | Use of 5,7,4'-trihydroxy flavanone or derivative thereof for analgesia | |
| RU2817847C1 (en) | Hyaluronic suppository with dimexid for treating rectal fissures | |
| CN102370777A (en) | Medicament for treating non-ulcerated chilblains | |
| CN102091136B (en) | Traditional Chinese medicine composition--external tincture for gall and preparation method thereof | |
| CN109954127A (en) | A kind of placental peptide injection | |
| CN105998335A (en) | Tranquilizing traditional Chinese medicine composition gel and preparation method thereof | |
| CN108939041A (en) | A kind of placental peptide injection | |
| CN1086295C (en) | Exterior-applied medical liquor | |
| Wang et al. | Effect of ear acupuncture plus injection at Zusanli (ST 36) on shoulder pain and cytokines after gynecologic laparoscopic surgery | |
| WO2017088177A1 (en) | Mussel adhesive protein product, and use thereof in preventing and suppressing neuronal inflammation | |
| CN104800286A (en) | Drug-loaded acupuncture needle capable of enhancing effects of promoting blood circulation and removing blood stasis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |